Yuko Nakamura1,2, Koji Matsumoto3, Toyomi Satoh1, Ken Nishide4, Akiko Nozue4, Koji Shimabukuro5, Seiichi Endo5, Kimihiro Nagai6, Akinori Oki1,6, Hiroyuki Ochi1, Yukio Morishita2, Masayuki Noguchi2, Hiroyuki Yoshikawa1. 1. Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Japan. 2. Department of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Japan. 3. Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8575, Japan. matsumok@mui.biglobe.ne.jp. 4. Department of Gynecology, Tsukuba Medical Center Hospital, Tsukuba, 305-8558, Japan. 5. Department of Obstetrics and Gynecology, Tsuchiura Kyodo General Hospital, Tsuchiura, 300-0053, Japan. 6. Department of Gynecology, Ibaraki Prefectural Central Hospital, Kasama, 309-1793, Japan.
Abstract
BACKGROUND: In cervical cancer screening programs, women with abnormal cytology are referred for colposcopy for histological evaluation. We examined whether a human papillomavirus (HPV) genotyping assay could be used to identify women who do not need immediate colposcopy and biopsy because of low risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+). METHODS: We prospectively evaluated test performance for 2 carcinogenic HPV genotypes (HPV16/18), for 8 types (HPV16/18/31/33/35/45/52/58), and for 13 types (HPV16/18/31/33/35/45/51/52/56/58/59/68) for prediction of histological CIN3+ results among 427 screen-positive women referred for colposcopy. The study subjects consisted of 214 women with low-grade squamous intraepithelial lesion (LSIL), 184 with high-grade squamous intraepithelial lesion (HSIL), and 29 with atypical squamous cells, cannot exclude HSIL (ASC-H). RESULTS: Among women with LSIL cytology, HPV16/18 positivity was 29.4 % and increased to 58.9 % for 8 types and to 74.8 % for 13 types (P < 0.001). The risk of CIN3+ biopsy results was still 7.9 % for women testing negative for HPV16/18, but decreased to 0.0 % for those testing negative for at least eight types of HPV (HPV16/18/31/33/35/45/52/58). Although HPV genotyping results enabled additional risk stratification among women with HSIL/ASC-H cytology, the risk of histological CIN3+ diagnosis among women testing negative for eight types or more was still sufficiently high (>35 %) to warrant immediate colposcopy referral. CONCLUSIONS: Of women with LSIL cytology, those testing negative for at least eight of the highest-risk types of HPV (HPV16/18/31/33/35/45/52/58) may not need immediate colposcopy and biopsy. This would reduce the number of colposcopy referrals by approximately 40 %. However, the HPV genotyping assay is not likely to alter the clinical management of women with HSIL/ASC-H.
BACKGROUND: In cervical cancer screening programs, women with abnormal cytology are referred for colposcopy for histological evaluation. We examined whether a human papillomavirus (HPV) genotyping assay could be used to identify women who do not need immediate colposcopy and biopsy because of low risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+). METHODS: We prospectively evaluated test performance for 2 carcinogenic HPV genotypes (HPV16/18), for 8 types (HPV16/18/31/33/35/45/52/58), and for 13 types (HPV16/18/31/33/35/45/51/52/56/58/59/68) for prediction of histological CIN3+ results among 427 screen-positive women referred for colposcopy. The study subjects consisted of 214 women with low-grade squamous intraepithelial lesion (LSIL), 184 with high-grade squamous intraepithelial lesion (HSIL), and 29 with atypical squamous cells, cannot exclude HSIL (ASC-H). RESULTS: Among women with LSIL cytology, HPV16/18 positivity was 29.4 % and increased to 58.9 % for 8 types and to 74.8 % for 13 types (P < 0.001). The risk of CIN3+ biopsy results was still 7.9 % for women testing negative for HPV16/18, but decreased to 0.0 % for those testing negative for at least eight types of HPV (HPV16/18/31/33/35/45/52/58). Although HPV genotyping results enabled additional risk stratification among women with HSIL/ASC-H cytology, the risk of histological CIN3+ diagnosis among women testing negative for eight types or more was still sufficiently high (>35 %) to warrant immediate colposcopy referral. CONCLUSIONS: Of women with LSIL cytology, those testing negative for at least eight of the highest-risk types of HPV (HPV16/18/31/33/35/45/52/58) may not need immediate colposcopy and biopsy. This would reduce the number of colposcopy referrals by approximately 40 %. However, the HPV genotyping assay is not likely to alter the clinical management of women with HSIL/ASC-H.
Authors: Jack Cuzick; J Thomas Cox; Guili Zhang; Mark H Einstein; Mark Stoler; Suzanne Trupin; Catherine M Behrens Journal: Int J Cancer Date: 2012-08-03 Impact factor: 7.396
Authors: Julia M L Brotherton; Masha Fridman; Cathryn L May; Genevieve Chappell; A Marion Saville; Dorota M Gertig Journal: Lancet Date: 2011-06-18 Impact factor: 79.321
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: K Kavanagh; K G J Pollock; A Potts; J Love; K Cuschieri; H Cubie; C Robertson; M Donaghy Journal: Br J Cancer Date: 2014-04-15 Impact factor: 7.640
Authors: Iris Babion; Barbara C Snoek; Putri W Novianti; Annelieke Jaspers; Nienke van Trommel; Daniëlle A M Heideman; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen; Saskia M Wilting Journal: Clin Epigenetics Date: 2018-06-07 Impact factor: 6.551